KRT8P39: A Potential Drug Target and Biomarker (G100418781)

Target Name: KRT8P39

NCBI ID: G100418781

KRT8P39

Other Name(s): keratin 8 pseudogene 39 | Keratin 8 pseudogene 39

KRT8P39: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KRTs) are a family of enzymes that regulate proteolytic enzymes, which are responsible for breaking down extracellular matrix (ECM) components and other structures. This family of enzymes has been identified as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. One of the most promising candidates for drug development is KRT8P39, which is a member of the KRT8 family and has been shown to have various physiological functions in the body.

KRT8P39 is a 25-kDa protein that is expressed in various tissues, including the brain, heart, liver, and kidneys. It is involved in the regulation of proteolytic enzymes, which are essential for the proper functioning of the immune system and other physiological processes. KRT8P39 functions as a negative regulator of the 尾-secretase (尾-S) enzyme, which is responsible for breaking down the intracellular proteinase 2 (ICP2) protein.

尾-S is a potent intracellular enzyme that is involved in the production of pro-inflammatory cytokines, which contribute to the development of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The dysfunction of 尾-S has been implicated in the development of these diseases, and targeting it with drugs has the potential to be a highly effective therapeutic approach.

KRT8P39 has been shown to regulate the activity of 尾-S enzyme in various cell types and tissues. For example, it has been shown to inhibit the activity of 尾-S in cancer cells, which can lead to the inhibition of the production of pro-inflammatory cytokines. Additionally, KRT8P39 has been shown to regulate the activity of 尾-S in the brain, which is involved in the development of neurodegenerative disorders.

In addition to its role in regulating 尾-S, KRT8P39 has also been shown to have other physiological functions. It is involved in the regulation of the production of extracellular matrix (ECM) components, which are essential for maintaining tissue structure and function. KRT8P39 has also been shown to regulate the production of angiotensin II, a potent regulator of blood pressure and cardiovascular function.

KRT8P39 has also been shown to have potential as a biomarker for various diseases. For example, it has been shown to be involved in the regulation of cancer cell proliferation, which can be used as a biomarker for the diagnosis and prognosis of cancer. Additionally, KRT8P39 has been shown to be involved in the regulation of neurodegenerative disorders, which can be used as a biomarker for the diagnosis and treatment of these disorders.

In conclusion, KRT8P39 is a promising candidate for drug development due to its involvement in the regulation of various physiological processes in the body. Its ability to regulate the activity of 尾-S and its potential as a biomarker for various diseases make it an attractive target for drug researchers. Further studies are needed to fully understand the role of KRT8P39 in the regulation of physiological processes and its potential as a drug target.

Protein Name: Keratin 8 Pseudogene 39

The "KRT8P39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT8P39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets